CEFPROZIL (cef'pro-zil)
Cefzil Classifications: antibiotic; second-generation cephalosporin; Therapeutic: antibiotic; cephalosporin Prototype: Cefaclor Pregnancy Category: B
|
Availability
250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension
Action
Semisynthetic, second-generation cephalosporin antibiotic with drug structure characterized by a beta-lactam ring; generally
resistant to hydrolysis by beta-lactamases. Preferentially binds to proteins in cell walls of susceptible organisms, thus
killing the bacteria.
Therapeutic Effect
Third-generation cephalosporins are more active and have a broader spectrum against gram-negative bacteria than first- or
second-generation of cephalosporins.
Uses
Upper and lower respiratory tract infections, otitis media, skin infections.
Contraindications
Hypersensitivity to cephalosporin and related antibiotics; severely impaired renal or hepatic function; phenylketonuria
(PKU); infants <6 mo.
Cautious Use
Patients with delayed reaction to penicillin or other drugs; coagulopathy; renal impairment, renal disease; GI disease,
especially colitis; pregnancy (category B).
Route & Dosage
Mild to Moderate Infections Adult: PO 250500 mg q1224h for 1014 d Child (>6 mo): PO 15 mg/kg q12h
|
Administration
Oral
- Drug may be given without regard to meals.
- Consult physician for patients with impaired renal function. Dose is reduced by 50% when creatinine clearance is 030
mL/min.
- Administer after hemodialysis since drug is partially removed by dialysis.
- After reconstitution, oral suspension is refrigerated. Discard unused portion after 14 d.
Adverse Effects (≥1%)
Body as a Whole: Hypersensitivity reactions, superinfections.
GI: Nausea, vomiting,
diarrhea, abdominal pain.
Hematologic: Eosinophilia.
CNS: Headache.
Skin: Rash, diaper rash.
Urogenital: Genital pruritus, vaginal
candidiasis.
Diagnostic Test Interference
May cause a positive direct Coombs' test; false-negative results in the ferricyanide assay for blood glucose; false-positive reactions for urine glucose with copper reduction tests such as Benedict's or Fehling's solution or Clinitest tablets; increased partial thromboplastin time, indicating thrombocytosis, eosinophilia; minor elevations in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin.
Interactions
Drug: Probenecid prolongs the elimination of cefprozil.
Pharmacokinetics
Absorption: Readily from GI tract.
Peak: 12 h.
Distribution: Distributes into blister fluid at 50% of the
serum level.
Elimination: Primarily by kidneys.
Half-Life: 12 h.
Nursing Implications
Assessment & Drug Effects
- Determine previous hypersensitivity to cephalosporins or penicillins before treatment.
- Withhold drug and notify physician if hypersensitivity occurs (e.g., rash, urticaria).
- Lab tests: Perform culture and sensitivity tests before and periodically during therapy. Therapy may be initiated while
results are pending.
- Monitor for and report diarrhea, as pseudomembranous colitis is a potential adverse effect.
- Monitor for and report signs of superinfection (see Appendix F).
- When given concurrently with other cephalosporins or aminoglycosides, monitor for signs of nephrotoxicity.
Patient & Family Education
- Complete the prescribed course of therapy, even if symptom free.
- Report rash or other signs of hypersensitivity immediately.
- Report signs of superinfection (see Appendix F).
- Report loose stools and diarrhea even after completion of drug therapy.